In April 2023, Dr. Reddy's Laboratories, an Indian-based global pharmaceutical company, has recently introduced Treprostinil, a hypertension injection, into the US market. The US Food and Drug Administration (USFDA) has approved the injection as a therapeutic equivalent generic version of Remodulin. It is used to treat pulmonary arterial hypertension. This condition causes high blood pressure in the arteries that carry blood to the lungs, leading to shortness of breath, fatigue, and chest pain.

Treprostinil injection belongs to a group of agents called prostacyclin mimetics used for the treatment of pulmonary arterial hypertension to diminish symptoms associated with exercise. Studies establishing effectiveness included patients with NYHA Functional Class II-IV (mild shortness of breath) symptoms.

Pulmonary arterial hypertension is a condition where blood vessels in the lungs become narrow, making it difficult for blood to flow. The injection relaxes blood vessels and increases blood supply to the lungs, helping improve symptoms associated with exercise.

The drug’s most common adverse reactions (incidence more than 3%) reported in clinical studies are subcutaneous infusion site pain and reaction, headache, diarrhea, nausea, jaw pain, vasodilatation, edema, and hypotension.

In recent news, the company had roped in actor and philanthropist Sonu Sood as its brand ambassador for the ready-to-serve fruit beverage segment Rebalanz Vitors.

Eris Lifesciences had acquired nine dermatology brands from Dr. Reddy's for Rs 275 crore. Moreover, the company's Q3 earnings report in December showed consolidated revenue at Rs 6,790 crore, up 27.2 percent from the year-ago quarter. The revenue surge was mainly led by the introduction of new products and increasing volumes, and profit after tax (PAT) jumped by a significant 75.4 percent to Rs 1,244 crore compared to a year ago.

The launch of Treprostinil injection in the US market is expected to strengthen Dr. Reddy's Laboratories' position in the global pharmaceutical industry and provide a cost-effective treatment option for patients with pulmonary arterial hypertension.